Insider Selling: Disc Medicine (NASDAQ:IRON) CFO Sells 400 Shares of Stock

Key Points

• CFO Jean Franchi sold 400 shares of Disc Medicine at an average price of $69.00 on April 13, totaling $27,600, and now directly owns 70,590 shares (a 0.56% reduction in her position).
• Shares traded at $70.18 (down $0.30) with a market cap of $2.68B and a 12‑month range of $39.20–$99.50; Disc is a clinical‑stage biotech reporting negative results (Q4 EPS -$1.62 and revenue of -$19.88M) and a negative PE of -11.72.
• Analyst sentiment is mixed but tilted positive: Disc Medicine has a consensus rating of "Moderate Buy" with an average price target of $104.80 (10 Buys, 1 Hold, 1 Sell), though several firms have recently trimmed targets.

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CFO Jean Franchi sold 400 shares of Disc Medicine stock in a transaction on Monday, April 13th. The stock was sold at an average price of $69.00, for a total value of $27,600.00. Following the completion of the sale, the chief financial officer directly owned 70,590 shares of the company's stock, valued at $4,870,710. The trade was a 0.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Disc Medicine Stock Performance

Shares of IRON traded down $0.30 during trading hours on Wednesday, hitting $70.18. The stock had a trading volume of 300,163 shares, compared to its average volume of 660,190. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 21.94. Disc Medicine, Inc. has a 12 month low of $39.20 and a 12 month high of $99.50. The firm has a market capitalization of $2.68 billion, a PE ratio of -11.72 and a beta of 0.91. The stock has a fifty day moving average price of $64.99 and a 200 day moving average price of $76.18.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) EPS for the quarter, topping the consensus estimate of ($1.69) by $0.07. The firm had revenue of ($19.88) million during the quarter, compared to the consensus estimate of $0.15 million. Analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on IRON shares. Cantor Fitzgerald cut their price objective on Disc Medicine from $153.00 to $125.00 and set an "overweight" rating for the company in a report on Tuesday, February 17th. Raymond James Financial reissued a "market perform" rating on shares of Disc Medicine in a report on Thursday, January 15th. Truist Financial cut their price target on Disc Medicine from $114.00 to $83.00 and set a "buy" rating for the company in a report on Friday, February 27th. Wedbush cut their price target on Disc Medicine from $110.00 to $88.00 and set an "outperform" rating for the company in a report on Tuesday, February 17th. Finally, Morgan Stanley set a $75.00 price target on Disc Medicine in a report on Tuesday, February 17th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Disc Medicine currently has a consensus rating of "Moderate Buy" and an average target price of $104.80.

Hedge Funds Weigh In On Disc Medicine

Hedge funds have recently made changes to their positions in the business. ANTIPODES PARTNERS Ltd bought a new position in shares of Disc Medicine in the fourth quarter worth about $33,000. Aster Capital Management DIFC Ltd bought a new position in shares of Disc Medicine in the third quarter worth about $38,000. KBC Group NV bought a new position in shares of Disc Medicine in the fourth quarter worth about $80,000. Avanza Fonder AB boosted its stake in shares of Disc Medicine by 54.0% in the third quarter. Avanza Fonder AB now owns 1,668 shares of the company's stock worth $110,000 after acquiring an additional 585 shares during the period. Finally, Persistent Asset Partners Ltd bought a new position in shares of Disc Medicine in the fourth quarter worth about $141,000. Institutional investors own 83.70% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.